Hyperthermic Intraperitoneal Chemotherapy is a specialized cancer treatment approach used to manage tumors that spread within the abdominal cavity, particularly along the peritoneal lining. This technique combines extensive surgical tumor removal with the direct circulation of heated chemotherapy inside the abdomen. Because the chemotherapy is delivered locally rather than through the bloodstream, it can reach microscopic cancer cells at high concentration while reducing systemic exposure. At an international Oncology Conference, this treatment is frequently discussed as an important strategy for selected patients with abdominal surface malignancies. A closely related term often used in surgical oncology literature is HIPEC Therapy, which refers to the same procedure involving heated intraperitoneal drug perfusion after cytoreductive surgery.

This treatment is most commonly considered for cancers such as appendiceal tumors, colorectal cancer with peritoneal spread, ovarian cancer, mesothelioma of the peritoneum, and certain gastric cancers that remain confined to the abdominal cavity. These diseases often produce tumor deposits across the peritoneal surfaces, where conventional intravenous chemotherapy may have limited penetration. Hyperthermic intraperitoneal chemotherapy addresses that challenge by allowing physicians to expose the abdominal cavity directly to chemotherapy drugs. The addition of controlled heat improves penetration into tissues and may increase the sensitivity of tumor cells to the treatment, enhancing cytotoxic effectiveness against residual microscopic disease.

The procedure usually begins with cytoreductive surgery, during which the surgical team removes all visible tumor deposits from the abdominal cavity as thoroughly as possible. This phase is essential because HIPEC is intended to treat residual microscopic disease rather than replace tumor debulking. Once visible disease has been removed, a heated chemotherapy solution is circulated through the abdomen using a closed or open perfusion system for a set period of time. The temperature is typically maintained between approximately 41 and 43 degrees Celsius, which helps increase drug activity without causing unacceptable injury to normal tissues. The goal is to destroy microscopic cancer cells that may remain on peritoneal surfaces after surgery.

Research over the years has shown that carefully selected patients may benefit significantly from this approach, particularly when disease is limited to the peritoneal cavity and complete or near-complete cytoreduction is possible. Patient selection remains one of the most important factors influencing outcomes, since tumor type, disease burden, performance status, and surgical feasibility all affect long-term benefit. Ongoing clinical studies continue to evaluate optimal drug regimens, duration of perfusion, surgical techniques, and the role of HIPEC across different cancers. As evidence expands, hyperthermic intraperitoneal chemotherapy continues to be explored as a highly specialized but potentially valuable treatment option within multidisciplinary cancer care.